On Friday, Prime Medicine Inc (NASDAQ: PRME) opened lower -0.70% from the last session, before settling in for the closing price of $4.31. Price fluctuations for PRME have ranged from $3.99 to $13.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -25.00% over the last five years. Company’s average yearly earnings per share was noted 20.09% at the time writing. With a float of $50.58 million, this company’s outstanding shares have now reached $97.38 million.
The firm has a total of 234 workers. Let’s measure their productivity. In terms of profitability, gross margin is 86.77%, operating margin of -327.86%, and the pretax margin is -339.61%.
Prime Medicine Inc (PRME) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Prime Medicine Inc is 57.86%, while institutional ownership is 36.58%. The most recent insider transaction that took place on Feb 15 ’24, was worth 20,000,000. In this transaction Director of this company bought 3,200,000 shares at a rate of $6.25, taking the stock ownership to the 3,200,000 shares. Before that another transaction happened on Feb 15 ’24, when Company’s 10% Owner bought 3,200,000 for $6.25, making the entire transaction worth $20,000,000. This insider now owns 3,200,000 shares in total.
Prime Medicine Inc (PRME) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 20.09% per share during the next fiscal year.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Check out the current performance indicators for Prime Medicine Inc (PRME). In the past quarter, the stock posted a quick ratio of 8.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 870.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.13, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -1.56 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Analysing the last 5-days average volume posted by the [Prime Medicine Inc, PRME], we can find that recorded value of 0.39 million was lower than the volume posted last year of 0.76 million. As of the previous 9 days, the stock’s Stochastic %D was 25.93%. Additionally, its Average True Range was 0.34.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 6.78%, which indicates a significant decrease from 39.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.32% in the past 14 days, which was lower than the 87.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.09, while its 200-day Moving Average is $6.61. Now, the first resistance to watch is $4.38. This is followed by the second major resistance level at $4.47. The third major resistance level sits at $4.56. If the price goes on to break the first support level at $4.19, it is likely to go to the next support level at $4.10. Should the price break the second support level, the third support level stands at $4.01.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are currently 120,031K shares outstanding in the company with a market cap of 513.73 million. Presently, the company’s annual sales total 0 K according to its annual income of -198,130 K. Last quarter, the company’s sales amounted to 590 K and its income totaled -45,760 K.
